Compare Inovio Pharmaceuticals Inc (INO) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while iShares 20 Plus Year Treasury Bond ETF trades at $83.67. Which is the better fit depends on your goals.
| INO | TLT | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | — |
52-Week High | $2.87 | $92.06 |
52-Week Low | $1.05 | $83.02 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $83.89, down 0.75% on the day. Technical indicators signal a bearish trend with moving averages showing selling pressure, while oscillators are neutral. The ETF has faced significant outflows amid rising interest rate concerns, with recent articles highlighting competition from cash ETFs and corporate bond alternatives offering higher yields. Dividend payments remain consistent but modest.
The outlook for TLT hinges on Federal Reserve policy shifts; potential rate cuts could boost long-term bonds, but persistent inflation risks may extend volatility. Investors face duration risk and opportunity cost versus shorter-term instruments. Wall Street sentiment is mixed, with some seeing value at current yields after steep declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
